Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
RESEARCH TOOLSreports
CTNM Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CTNM Stock 12 Month Forecast
Average Price Target
$24.50
▲(96.00% Upside)
| Highest Price Target$29.00 | Average Price Target$24.50 | Lowest Price Target$21.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
09/18/25
Analysts' Top NA Picks: Rubrik, Inc. Class A (RBRK), Contineum Therapeutics, Inc. Class A (CTNM)We provide additional detail in the full note. We also highlight a recent publication from Contineum on preclinical data of PIPE-791 in treating lung fibrosis and IPF (Poon et al., 2025 Respiratory Research), which shows enhanced selectivity and potency compared to admilparant and also that LPAR1 expression is only upregulated in human lung slices from IPF patients. The latter may explain why lung PET in healthyvolunteers enrolled in the Phase Ib was difficult to capture and no IPF patients were part of the study in the end as previously disclosed. Stock Thoughts: We view data from the Phase Ib as an incremental win for the company as it advances its first wholly owned asset PIPE-791 in both IPF and pain indications.
JonesTrading
$23
Buy
84.00%
Upside
Reiterated
09/18/25
Morgan Stanley
$21
Buy
68.00%
Upside
Reiterated
09/18/25
Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b ResultsWe note that in brain, PIPE-791 achieved meaningful receptor occupancy in both healthy volunteers and patients with progressive MS. While lung receptor occupancy was not viable, we see this as a known limitation (low levels of LPA1R in healthy lungs, and hurdles imaging vs. brain). As an aside, we note the corporate slide deck demonstrates a meaningfully elevated LPA1R expression level in IPF donor lung sections ( Exhibit 1 ), giving us confidence LPA1R has a meaningful role IPF pathology. Moreover, we believe the brain PET and receptor occupancy values are encouraging for leveraging LPA1R antagonism in both PrMS and IPF. Importantly, we see a best-in-class PK signature for an LPA1R antagonist, where even 1mg 1 exceeded EC50 ( Exhibit 2 ) for >24 hours, and 1mg Day 7 target coverage exceeded EC90 for >24 hours.
Stifel Nicolaus
$29
Buy
132.00%
Upside
Reiterated
08/06/25
Contineum Therapeutics, Inc. (CTNM, $6.00, Buy; Target $29.00) – 'We're reiterating our Buy rating on CTNM' following the 2Q25 update.
RBC Capital
$25
Buy
100.00%
Upside
Reiterated
08/05/25
Robert W. Baird
$32→$16
Buy
28.00%
Upside
Reiterated
03/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
09/18/25
Analysts' Top NA Picks: Rubrik, Inc. Class A (RBRK), Contineum Therapeutics, Inc. Class A (CTNM)We provide additional detail in the full note. We also highlight a recent publication from Contineum on preclinical data of PIPE-791 in treating lung fibrosis and IPF (Poon et al., 2025 Respiratory Research), which shows enhanced selectivity and potency compared to admilparant and also that LPAR1 expression is only upregulated in human lung slices from IPF patients. The latter may explain why lung PET in healthyvolunteers enrolled in the Phase Ib was difficult to capture and no IPF patients were part of the study in the end as previously disclosed. Stock Thoughts: We view data from the Phase Ib as an incremental win for the company as it advances its first wholly owned asset PIPE-791 in both IPF and pain indications.
JonesTrading
$23
Buy
84.00%
Upside
Reiterated
09/18/25
Morgan Stanley
$21
Buy
68.00%
Upside
Reiterated
09/18/25
Promising Potential of PIPE-791: Buy Rating for Contineum Therapeutics Amid Positive Phase 1b ResultsWe note that in brain, PIPE-791 achieved meaningful receptor occupancy in both healthy volunteers and patients with progressive MS. While lung receptor occupancy was not viable, we see this as a known limitation (low levels of LPA1R in healthy lungs, and hurdles imaging vs. brain). As an aside, we note the corporate slide deck demonstrates a meaningfully elevated LPA1R expression level in IPF donor lung sections ( Exhibit 1 ), giving us confidence LPA1R has a meaningful role IPF pathology. Moreover, we believe the brain PET and receptor occupancy values are encouraging for leveraging LPA1R antagonism in both PrMS and IPF. Importantly, we see a best-in-class PK signature for an LPA1R antagonist, where even 1mg 1 exceeded EC50 ( Exhibit 2 ) for >24 hours, and 1mg Day 7 target coverage exceeded EC90 for >24 hours.
Stifel Nicolaus
$29
Buy
132.00%
Upside
Reiterated
08/06/25
Contineum Therapeutics, Inc. (CTNM, $6.00, Buy; Target $29.00) – 'We're reiterating our Buy rating on CTNM' following the 2Q25 update.
RBC Capital
$25
Buy
100.00%
Upside
Reiterated
08/05/25
Robert W. Baird
$32→$16
Buy
28.00%
Upside
Reiterated
03/07/25
Best Analysts Covering Contineum Therapeutics, Inc. Class A
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+15.34%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +15.34% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+63.98%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +63.98% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+112.54%
reiterated a buy rating 3 days ago
Copying Debanjana Chatterjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +112.54% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+112.54%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +112.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CTNM Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
5
7
4
8
7
Buy
1
1
1
2
3
Hold
1
0
0
0
0
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
8
9
6
10
10
Each month's total comprises the sum of three months' worth of ratings.
CTNM Financial Forecast
CTNM Stock Forecast FAQ
What is CTNM’s average 12-month price target, according to analysts?
Based on analyst ratings, Contineum Therapeutics, Inc. Class A’s 12-month average price target is 24.50.
What is CTNM’s upside potential, based on the analysts’ average price target?
Contineum Therapeutics, Inc. Class A has 96.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CTNM a Buy, Sell or Hold?
Contineum Therapeutics, Inc. Class A has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is Contineum Therapeutics, Inc. Class A’s price target?
The average price target for Contineum Therapeutics, Inc. Class A is 24.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $21.00. The average price target represents 96.00% Increase from the current price of $12.5.
The highest analyst price target is $29.00 ,the lowest forecast is $21.00. The average price target represents 96.00% Increase from the current price of $12.5.
What do analysts say about Contineum Therapeutics, Inc. Class A?
Contineum Therapeutics, Inc. Class A’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of CTNM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.